We have also investigated the effects of specific knockdown of HER3 on TNBC cell proliferation in vitro and tumor growth in vivo, and explored whether our anti-HER3 mAb 4A7 would potentiate the antitumor activity of gefitinib and/or paclitaxel against TNBC. This evidence concerns the gene ERBB3 and neoplasm.